Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Living Cell Technologies ( (AU:1AI) ) is now available.
Algorae Pharmaceuticals Limited has applied to the Australian Securities Exchange for quotation of 7,377,816 new ordinary fully paid shares under its existing ticker 1AI. The new securities, issued on February 27, 2026, arise from the exercise or conversion of previously outstanding options or other convertible instruments, modestly expanding the company’s free float and potentially increasing liquidity for shareholders.
The application formalizes the admission of these additional shares to trading on the ASX and reflects ongoing capital structuring activity within the company. While no specific use of proceeds is disclosed in the filing, the enlarged quoted capital base may provide Algorae Pharmaceuticals with greater financial flexibility and a broader shareholder base as it pursues its pharmaceutical development objectives.
The most recent analyst rating on (AU:1AI) stock is a Sell with a A$0.02 price target. To see the full list of analyst forecasts on Living Cell Technologies stock, see the AU:1AI Stock Forecast page.
More about Living Cell Technologies
Algorae Pharmaceuticals Limited is an Australian-listed pharmaceutical company, trading on the ASX under the code 1AI. The firm operates in the life sciences sector, focusing on drug development and related biopharmaceutical activities, with its securities listed for trading on the Australian Securities Exchange.
YTD Price Performance: 21.43%
Average Trading Volume: 2,043,058
Technical Sentiment Signal: Buy
Current Market Cap: A$30.61M
For a thorough assessment of 1AI stock, go to TipRanks’ Stock Analysis page.